GALECTIN THERAPEUTICS INC
GALTNASDAQ🏆 #2561 by market capUS Equity
$486.59▼ $2.82 (−0.58%)
Simulated price1h—
24h▼ 0.6%
7d—
14d—
30d—
1y—
🏦Market Cap
$316M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
52
Weak
No chart data available for GALT.
Trading Snapshot
- Day Range
- $484.43 – $491.51
- 52-Week Range
- $2.03 – $7.13
- Volume
- $2.48B
- Avg Volume
- $2.89B
- Shares Outstanding
- 65.9M
- Next Earnings
- Oct 24, 2026
Fundamentals Snapshot
- Annual Revenue
- $61M
- Last Q Revenue
- $15M
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- $-0.41
- Dividend Yield
- —
Why Investors Own GALT
- ✓High-growth profile — revenue up +10.0% YoY with expanding US Equity exposure.
- ✓Healthy economics — 58% gross margin and 26% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$61M▲ +14.0% YoY
Gross Margin (TTM)
57.6%▲ +4.0% YoY
Operating Income (TTM)
$17M▲ +14.0% YoY
Free Cash Flow (TTM)
$16M▲ +14.0% YoY
About GALECTIN THERAPEUTICS INC
A company profile for GALECTIN THERAPEUTICS INC isn’t available yet — check back soon.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Weak
52/100
Analyst Price Target
ⓘAverage Target
$616.98
▲ +26.8% Upside
High Target$668.05
Low Target$566.31
Based on 35 analysts
Latest News & Updates
🚀
Reuters·2h ago
GALECTIN THERAPEUTICS INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
Barron’s·5h ago
Analysts lift GALT price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
Bloomberg·1d ago
GALECTIN THERAPEUTICS INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.